Why the study?
Does lusutrombopag increase platelet counts and prevent the need for platelet transfusions in patients with chronic liver disease and thrombocytopenia scheduled for invasive procedures?
Does lusutrombopag increase platelet counts and prevent the need for platelet transfusions in patients with chronic liver disease and thrombocytopenia scheduled for invasive procedures?
Lusutrombopag effectively increases platelet counts and reduces the need for platelet transfusions in patients with chronic liver disease undergoing invasive procedures, though its efficacy may be attenuated in patients with diabetes mellitus.
May reduce transfusion needs before procedures; leaves open confirmation of repeatable efficacy in prospective trials.
/μL before the invasive procedure (p<0.01), and patients undergoing 49 of the 53 (92%) treatment regimens succeeded in undergoing invasive procedures without needing platelet transfusions. In patients who received lusutrombopag treatment repeatedly, the median platelet count significantly increased following the second administration of lusutrombopag, and the effects of lusutrombopag were similar between the first and second administration. A multivariate analysis identified the absence of diabetes mellitus (odds ratio, 5.56 for presence; p=0.04) as a significant and independent predictor of a response to lusutrombopag. Conclusion Lusutrombopag treatment significantly increased platelet counts in patients with chronic liver disease, making it possible to receive invasive procedures. The treatment produced identical effects when it was repeated. The efficacy of lusutrombopag might be decreased in patients with diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Nishida et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: